How is Intellia Therapeutics funded?
Intellia Therapeutics's current capital profile is Public company; Nasdaq: NTLA.
- Status
- Public company; Nasdaq: NTLA
- Funding type
- Public-market financed
- Latest signal
- Use current filings, investor materials, and company news
- Budget signal
- Look for product launches, acquisitions, hiring, capex, and earnings commentary
- Procurement maturity
- Public company operating environment
- Seller angle
- Tie outreach to active initiatives and operating leverage
Intellia Therapeutics's funding and ownership milestones
Intellia Therapeutics's ownership context is summarized from public-company and official source signals.
- FoundingCompany foundedInitial company formation and market development.
- ScaleOperating scale reachedThe company developed a repeatable customer, product, or distribution base.
- CurrentPublic company; Nasdaq: NTLACurrent listing status as of June 2026.
Sources:Intellia Therapeutics official websiteIntellia Therapeutics investor relations or company news
What is Intellia Therapeutics's current ownership status?
Intellia Therapeutics's current status is Public company; Nasdaq: NTLA. Sellers should verify current listing status and investor materials before account planning.
What does Intellia Therapeutics's capital profile mean for sales timing?
A public company with this profile usually has defined budget owners, planning cycles, procurement review, and measurable operating priorities.
What seller signals matter most?
The most useful signals are leadership changes, acquisitions, geographic expansion, product launches, public guidance, partner programs, capital expenditure plans, and new hiring clusters.
As of June 2026.Sources:Intellia Therapeutics official websiteIntellia Therapeutics investor relations or company newsBuiltWith public technology profile
Intellia Therapeutics — frequently asked questions
